Filtered By:
Specialty: Hematology
Nutrition: Vitamins

This page shows you your search results in order of relevance.

Order by Relevance | Date

Total 228 results found since Jan 2013.

Predicting Adverse Events beyond Stroke and Bleeding with the ABC-Stroke and ABC-Bleeding Scores in Patients with Atrial Fibrillation: The Murcia AF Project.
CONCLUSION:  In AF patients, the ABC-stroke and ABC-bleeding scores demonstrated similar predictive ability for outcomes beyond stroke and bleeding, including MI, acute HF, a composite of cardiovascular events, and all-cause deaths. This is consistent with nonspecificity of biomarkers that predict "sick" patients or poor prognosis overall. PMID: 32506417 [PubMed - as supplied by publisher]
Source: Thrombosis and Haemostasis - June 6, 2020 Category: Hematology Authors: Camelo-Castillo A, Rivera-Caravaca JM, Marín F, Vicente V, Lip GYH, Roldán V Tags: Thromb Haemost Source Type: research

Efficacy and safety of edoxaban in comparison with dabigatran, rivaroxaban and apixaban for stroke prevention in atrial fibrillation. An indirect comparison analysis.
Abstract Large Phase 3 clinical trials for stroke prevention in atrial fibrillation (AF) have compared non-vitamin K antagonist oral anticoagulants (NOACs) against warfarin, with the edoxaban trial only recently reported. In the absence of head to head trials directly comparing these NOACs against each other, we compared the efficacy and safety of edoxaban to other agents by an indirect comparison analysis. We performed an indirect comparison analysis of edoxaban (2 dose strategies) against apixaban (1 dose), dabigatran etexilate (2 doses) and rivaroxaban (1 dose), for their relative efficacy and safety against ea...
Source: Thrombosis and Haemostasis - February 28, 2014 Category: Hematology Authors: Skjøth F, Larsen TB, Rasmussen LH, Lip GY Tags: Thromb Haemost Source Type: research

Use of Non-vitamin K Antagonist Oral Anticoagulants for Stroke Prevention across the Stroke Spectrum: Progress and Prospects.
Abstract Multiple randomized controlled trials and many real-world evidence studies have consistently shown that non-vitamin K antagonist oral anticoagulants (NOACs) are preferable to vitamin K antagonists for thromboembolic stroke prevention in the majority of patients with atrial fibrillation (AF). However, their role in the management of patients with AF and comorbidities, as well as in other patient populations with a high risk of stroke, such as patients with prior embolic stroke of undetermined source (ESUS) and those with atherosclerosis, is less clear. There is now increasing evidence suggesting that NOACs...
Source: Thrombosis and Haemostasis - January 7, 2021 Category: Hematology Authors: Camm AJ, Atar D Tags: Thromb Haemost Source Type: research

Impact of pre-admission treatment with non-vitamin K oral anticoagulants on stroke severity in patients with acute ischemic stroke
ConclusionsWe report a positive impact of pre-admission NOAC on ischemic stroke severity, which is particularly remarkable in light of the increased prevalence of prior stroke and lower rates of thrombolysis in this patient population.
Source: Journal of Thrombosis and Thrombolysis - February 23, 2018 Category: Hematology Source Type: research

Adequacy of preadmission oral anticoagulation with vitamin K antagonists and ischemic stroke severity and outcome in patients with atrial fibrillation
In conclusion, optimally anticoagulated patients with AF have more favorable functional outcome after stroke and a trend for less severe stroke whereas patients with subtherapeutic anticoagulation have similar stroke severity and outcome with those on no treatment.
Source: Journal of Thrombosis and Thrombolysis - August 8, 2015 Category: Hematology Source Type: research

Beyond Stroke Prevention in Atrial Fibrillation: Exploring Further Unmet Needs with Rivaroxaban.
This article provides an update on three randomized controlled trials of rivaroxaban, a direct, oral factor Xa inhibitor, that are complete or are ongoing, in these unmet areas of stroke prevention: oPen-label, randomized, controlled, multicentre study explorIng twO treatmeNt stratEgiEs of Rivaroxaban and a dose-adjusted oral vitamin K antagonist treatment strategy in patients with Atrial Fibrillation who undergo Percutaneous Coronary Intervention (PIONEER AF-PCI) trial; the New Approach riVaroxaban Inhibition of factor Xa in a Global trial vs Aspirin to prevenT Embolism in Embolic Stroke of Undetermined Source (NAVIGATE E...
Source: Thrombosis and Haemostasis - March 22, 2018 Category: Hematology Authors: Gibson CM, Hankey GJ, Nafee T, Welsh RC Tags: Thromb Haemost Source Type: research

Circulating desphospho-uncarboxylated matrix Gla protein and the risk of coronary heart disease and stroke.
CONCLUSION: The average follow-up was 11.5 years. Dp-ucMGP concentrations were not associated with CHD risk with a HR per SD of 1.00 (95% CI: 0.93-1.07) and a HR Q4 vs Q1 of 0.94 (95% CI: 0.79-1.13) after adjustment for cardiovascular risk factors. Dp-ucMGP was not associated with stroke risk (HRSD 0.98;95% CI: 0.90-1.08 and a HR Q4 vs Q1 of 1.09;95% CI: 0.78-1.51). This study could not confirm that high dp-ucMGP concentrations, reflecting a poor vitamin K status, are associated with increased CHD or stroke risk in the general population. This article is protected by copyright. All rights reserved. PMID: 24826813 [Pub...
Source: Thrombosis and Haemostasis - May 15, 2014 Category: Hematology Authors: Dalmeijer GW, van der Schouw YT, Magdeleyns EJ, Vermeer C, Verschuren WM, Boer JM, Beulens JW Tags: J Thromb Haemost Source Type: research

Spotlight on unmet needs in stroke prevention: The PIONEER AF-PCI, NAVIGATE ESUS and GALILEO trials.
This article focuses on three randomised controlled trials (RCTs) that are investigating the utility of rivaroxaban, a direct, oral, factor Xa inhibitor, in additional areas of stroke prevention where data for anticoagulants are lacking: oPen-label, randomized, controlled, multicentre study explorIng twO treatmeNt stratEgiEs of Rivaroxaban and a dose-adjusted oral vitamin K antagonist treatment (PIONEER AF-PCI); New Approach riVaroxoban Inhibition of factor Xa in a Global trial vs Aspirin to prevenT Embolism in Embolic Stroke of Undetermined Source (NAVIGATE ESUS); and Global study comparing a rivAroxaban-based antithrombo...
Source: Thrombosis and Haemostasis - September 13, 2016 Category: Hematology Authors: Hemmrich M, Peterson ED, Thomitzek K, Weitz JI Tags: Thromb Haemost Source Type: research

Stroke Severity in Patients on Non-Vitamin K Antagonist Oral Anticoagulants with a Standard or Insufficient Dose.
CONCLUSION:  Use of warfarin with a therapeutic intensity or standard-dosed NOACs was associated with a relatively mild stroke in the patients with NVAF. PMID: 30453351 [PubMed - as supplied by publisher]
Source: Thrombosis and Haemostasis - November 19, 2018 Category: Hematology Authors: Jung YH, Choi HY, Lee KY, Cheon K, Han SW, Park JH, Cho HJ, Park HJ, Nam HS, Heo JH, Lee HS, Kim YD Tags: Thromb Haemost Source Type: research

Relationship between temporal rhythm-based classification of atrial fibrillation and stroke: real-world vs. clinical trial
ConclusionsOverall, our results support the need for anticoagulation based on thromboembolic risk profile rather than AF type.
Source: Journal of Thrombosis and Thrombolysis - April 15, 2022 Category: Hematology Source Type: research

Circulating desphospho‐uncarboxylated matrix Gla protein and the risk of coronary heart disease and stroke
This study could not confirm that high dp‐ucMGP concentrations, reflecting a poor vitamin K status, are associated with increased CHD or stroke risk in the general population.This article is protected by copyright. All rights reserved.
Source: Journal of Thrombosis and Haemostasis - April 1, 2014 Category: Hematology Authors: Geertje W. Dalmeijer, Yvonne T. Schouw, Elke J. Magdeleyns, Cees Vermeer, W.M. Monique Verschuren, Jolanda M.A. Boer, Joline W.J. Beulens Tags: Original Article ‐ Clinical Haemostasis and Thrombosis Source Type: research

Microfluidic coagulation assay for monitoring anticoagulant therapy in acute stroke patients.
In conclusion, the SAW-CT assay is capable to monitor anticoagulant level and effect in patients receiving dabigatran, rivaroxaban and the VKA phenprocoumon. It has a limited sensitivity for apixaban-detection. If specific SAW-CT results were used as cut-offs, SAW-CT yields high diagnostic accuracy to exclude relevant rivaroxaban and dabigatran concentrations in stroke-patients. PMID: 28124061 [PubMed - as supplied by publisher]
Source: Thrombosis and Haemostasis - January 25, 2017 Category: Hematology Authors: Bluecher A, Meyer Dos Santos S, Ferreirós N, Labocha S, Meyer Dos Santos IM, Picard-Willems B, Harder S, Singer OC Tags: Thromb Haemost Source Type: research

2021 Focused Update Consensus Guidelines of the Asia Pacific Heart Rhythm Society on Stroke Prevention in Atrial Fibrillation: Executive Summary
Thromb Haemost. 2021 Nov 13. doi: 10.1055/s-0041-1739411. Online ahead of print.ABSTRACTThe consensus of the Asia Pacific Heart Rhythm Society (APHRS) on stroke prevention in atrial fibrillation (AF) has been published in 2017 which provided useful clinical guidance for cardiologists, neurologists, geriatricians, and general practitioners in the Asia-Pacific region. In these years, many important new data regarding stroke prevention in AF were reported. The practice guidelines subcommittee members comprehensively reviewed updated information on stroke prevention in AF, and summarized them in this 2021 focused update of the...
Source: Thrombosis and Haemostasis - November 13, 2021 Category: Hematology Authors: Tze-Fan Chao Boyoung Joung Yoshihide Takahashi Toon Wei Lim Eue-Keun Choi Yi-Hsin Chan Yutao Guo Charn Sriratanasathavorn Seil Oh Ken Okumura Gregory Y H Lip Source Type: research

Novel oral anticoagulants in secondary prevention of stroke
In patients with atrial fibrillation (AF) oral anticoagulation with vitamin-K antagonists (warfarin, phenprocoumon) is effective both for primary and secondary stroke prevention yielding a 60–70% relative reduction in stroke risk compared with placebo, as well as a mortality reduction of 26 percent. Vitamin-K antagonists have a number of well documented shortcomings. Recently the results of randomised trials for three new oral anticoagulants that do not exhibit the limitations of vitamin-K antagonists have been published. These include direct factor Xa inhibitors (rivaroxaban and apixaban) and a direct thrombin inhibitor...
Source: Best Practice and Research. Clinical Haematology - June 1, 2013 Category: Hematology Authors: H.C. Diener, J.D. Easton, G.J. Hankey, R.G. Hart Source Type: research